Tata India Pharma & Healthcare Fund
Pharma and Healthcare · Direct plan · Growth
₹40.23
+₹0.38 (+0.94%) today
NAV on 20 Nov 2026 · Near its 52-week high
Returns
Up to a year
| Period | This fund | NIFTY Pharma | Rank |
|---|---|---|---|
| 1 month | +9.87% | +10.85% | 16/19 |
| 3 months | +1.12% | +7.49% | 17/18 |
| 6 months | +7.63% | +14.69% | 17/18 |
| This year | +13.73% | +25.68% | 17/18 |
| 1 year | +11.82% | +25.88% | 16/17 |
Longer term
| This fund | NIFTY Pharma | NIFTY Pharma | Category | ||||
|---|---|---|---|---|---|---|---|
| Total | A year | Total | A year | A year | Rank | ||
| 2 years | +18.59% | +8.9% | +14.9% | – | |||
| 3 years | +67.50% | +18.8% | +22.4% | 11/12 | |||
| 5 years | +110.3% | +16.0% | +16.4% | 7/10 | |||
| 7 years | +306.8% | +22.2% | +21.0% | – | |||
| 10 years | +339.8% | +16.0% | +11.0% | – | |||
| Since inception | +302.3% | +13.6% | +9.3% | – | |||
₹1 lakh invested 10 years ago is ₹4.4 lakh today.
From the plan's own NAV, to 20 Nov 2026. Rank 1 is best. Past returns are no guide to the future.
RiskWorst fall -19.8% · volatility 16.6% a year
Volatility, 3 years
16.6%
NIFTY Pharma 15.6%
Worst fall
-19.8%
Aug 2017, back by Aug 2018
Worst calendar year
-13.1%
2016
Up months
64%
last 3 years
Against other pharma and healthcare funds, last 3 years (worst fall: 5 years)
Volatility
= 16.6%
In line with peers · average 16.0%
12 of 13
Worst fall
✓ -16.8%
Fell less than peers · average -18.2%
2 of 10
Sharpe ratio
! 0.81
Less return for the risk · average 0.99
10 of 12
Yearly cost
= 1.09%
About average · average 1.10%
12 of 18
More measures ›Fewer measures ‹
Sharpe ratio, 3 years
0.81
Return above the CRISIL Overnight Index per unit of volatility
Sortino ratio, 3 years
1.39
The same, counting only falls
Alpha vs NIFTY Pharma
-2.19%
Yearly return beyond what its beta explains
Beta vs NIFTY Pharma
0.91
Moves this much when the index moves 1%
Share of the index's rises
92%
In months the index rose
Share of the index's falls
101%
In months the index fell; lower is better
Over the last 3 years, from the fund's NAVs against the NIFTY Pharma.
Where it ranksAgainst 19 pharma and healthcare funds
Category rank, year by year
In the top half of pharma and healthcare funds in 3 of 10 calendar years.
Top quarter in 0, bottom quarter in 2.
17/18
Rank in 2026 YTD
'172017
Q3
3/4
'182018
Q2
2/4
'192019
Q2
3/7
'202020
Q4
7/9
'212021
Q3
6/9
'222022
Q2
3/10
'232023
Q3
6/10
'242024
Q3
8/13
'252025
Q3
12/16
'262026YTD
Q4
17/18
Each year ranks the pharma and healthcare funds by that year's return from their own Direct Growth NAV; Q1 is the top quarter. 2026 is year to date. The peer group is today's funds, so funds that closed or merged in earlier years are not counted. Past performance does not indicate future returns.
Where it ranks
among 19 pharma and healthcare funds, Direct plans1 year
16 of 17
Bottom quarter
3 years
11 of 12
Bottom quarter
5 years
7 of 10
Third quarter
Lowest cost
12 of 18
Third quarter
| Best over 3 years | 3 years | A year | Cost | Size |
|---|---|---|---|---|
| 1HDFC Pharma and Healthcare Fund | +123.0% | +30.6% | 1.04% | ₹3,666 Cr |
| 2SBI Healthcare Opportunities Fund | +94.4% | +24.8% | 1.00% | ₹6,067 Cr |
| 3Mirae Asset Healthcare Fund | +90.9% | +24.0% | 0.61% | ₹3,562 Cr |
| 4UTI Healthcare Fund | +87.3% | +23.3% | 1.34% | ₹1,433 Cr |
| 5LIC MF Healthcare Fund | +80.9% | +21.9% | 1.38% | ₹96.54 Cr |
| 11Tata India Pharma & Healthcare Fund this fund | +67.5% | +18.8% | 1.09% | ₹1,499 Cr |
Every fund in the category computed from its own NAV the same way, to 20 Nov 2026. All Pharma and Healthcare funds ›
What stands out
What it holds
43 holdings · as of Aug 2026
- 1Sun Pharmaceutical Industries Ltd8.43%
- 2Healthcare Global Enterprises Ltd6.30%
- 3Divi'S Laboratories Ltd5.65%
- 4Abbott India Ltd5.44%
- 5Rainbow Children'S Medicare Ltd4.47%
- 6Apollo Hospitals Enterprises Ltd4.32%
- 7Cipla Ltd4.27%
- 8Dr. Reddys Laboratories Ltd4.21%
- 9Max Healthcare Institute Ltd3.80%
- 10Fortis Healthcare Ltd3.30%
SIP returns of pharma and healthcare funds · All pharma and healthcare funds · Fund screener
About Tata India Pharma & Healthcare Fund Direct Plan Growth
Tata India Pharma & Healthcare Fund Direct Plan Growth is a Sector Specific - Pharma equity fund from Tata Asset Management Limited, launched on 28 Dec 2015. Its benchmark is the NIFTY Pharma Index. The expense ratio is 1.09% a year. It manages ₹1,499 crore. The NAV was ₹40.23 on 20 Nov 2026.
Questions about Tata India Pharma & Healthcare Fund
What is the NAV of Tata India Pharma & Healthcare Fund Direct Growth?
The NAV of Tata India Pharma & Healthcare Fund Direct Growth was ₹40.23 on 20 Nov 2026. Mutual fund NAVs are published once a day, after markets close.
What are the returns of Tata India Pharma & Healthcare Fund Direct Growth?
Tata India Pharma & Healthcare Fund Direct Growth returned 11.8% over 1 year, 18.8% a year over 3 years, 16.0% a year over 5 years and 16.0% a year over 10 years, to 20 Nov 2026, worked out from its own daily NAV. It returned more than the NIFTY Pharma Index in 8 of 10 calendar years since 2017.
What is the expense ratio of Tata India Pharma & Healthcare Fund Direct Growth?
1.09% a year. It is taken from the fund's assets every day, so the NAV and every return shown are already after this cost.
Can NRIs in the UAE invest in Tata India Pharma & Healthcare Fund?
NRIs can generally invest once KYC is complete, paying from an NRE or NRO account. Tata Mutual Fund does not accept investors living in the US or Canada, per its own documents checked on 15 Nov 2026. Rules change, so confirm with the fund house.
How are Tata India Pharma & Healthcare Fund gains taxed for NRIs?
India taxes gains on equity funds at 20% on units held 12 months or less, and at 12.5% on gains above ₹1.25 lakh a year on units held longer, plus cess and any surcharge. For NRIs the tax is deducted when units are redeemed. The UAE has no personal income tax, and the India UAE tax treaty may apply, so confirm your position with a tax adviser.
Rolling returns shows every period, not just the latest.
Compare every pharma and healthcare fund on returns, volatility, worst fall and cost.

















